ArticleCureus2025
Neurobiomarkers for Traumatic Brain Injury: Comparison of Serum Values Within 24 Hours of Injury With Glasgow Coma Scale (GCS) Scores in a Prospective Cohort Trial.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Association between neurofilament light chain concentrations and outcomes in patients with moderate to severe traumatic brain injury: a systematic review and meta-analysis.Critical care (London, England) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Traumatic brain injury (TBI) is a significant cause of morbidity, disability, and mortality across all age groups, presenting both health and socioeconomic challenges globally. Neuroimaging techniques are crucial for assessing TBI, but their availability is often limited. Investing in point-of-care blood biomarkers, such as neurofilament light (NFL) protein and S100 calcium-binding protein B (S100B), may offer more accessible and reliable information on neuronal injury, assisting in clinical evaluation without compromising sensitivity. The objective of this study was to correlate the serum values of NFL and S100B with the severity of TBI as assessed by the Glasgow coma scale and to evaluate the potential of these markers for early prognostication. Methods A total of 92 TBI patients, categorized into mild (30), moderate (28), and severe (34) cases, admitted to Nizam's Institute of Medical Sciences, Hyderabad, India, from 2019 to 2020, were enrolled. Serum levels of NFL and S100B were measured within 24-36 hours of injury for all participants. Results NFL concentrations were 51.1±12.13, 99.9±31.55, and 251.68±78.28 pg/mL for mild, moderate, and severe TBI patients, respectively. S100B concentrations were 193.47±76.57, 542.9±158.78, and 1882.6±824.8 pg/mL for mild, moderate, and severe TBI patients, respectively. Significant differences were observed in NFL and S100B levels when compared between the groups (p<0.05). On day 0, the values of NFL (p≤0.001) and S100B (p=0.023) were significantly higher in non-survivors compared to survivors in severe TBI. S100B showed AUCs of 0.98 (mild), 0.93 (moderate), and 0.99 (severe); NFL showed AUCs of 0.21, 0.51, and 0.28, respectively. The odds ratio (OR) for S100B in mild TBI was 1.07 (95% CI: 1.00-1.14); all other ORs were close to 1 with 95% CI including 1. Conclusion S100B showed strong diagnostic performance across TBI severities, while NFL demonstrated limited utility based on low AUC values and non-significant ORs. These findings support the use of S100B as a more reliable biomarker for TBI assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.